Baloxavir marboxil

Chemical formula: C₂₇H₂₃F₂N₃O₇S  Molecular mass: 571.55 g/mol 

Active ingredient description

Baloxavir marboxil is a prodrug that is converted by hydrolysis to baloxavir, the active form that exerts anti-influenza activity. Baloxavir acts on the cap-dependent endonuclease (CEN), an influenza virus-specific enzyme in the polymerase acidic (PA) subunit of the viral RNA polymerase complex and thereby inhibits the transcription of influenza virus genomes resulting in inhibition of influenza virus replication.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
J05AX25 J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AX Other antivirals
Discover more medicines within J05AX25

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
XOFLUZA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
XOFLUZA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 1985606-14-1
DrugBank Drug: DB13997
KEGG Drug: D11021
RxNorm Ingredient: 2099995
SNOMED-CT Concept: 782500006
Baloxavir marboxil (substance)
UNII Identifier: 505CXM6OHG
BALOXAVIR MARBOXIL

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.